UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000011438
Receipt No. R000013104
Scientific Title Exploratory Research on Prognosis Factors and Risk-factors of Adverse Drug Reactions in the Adjuvant Chemotherapy with S-1 for Patients with Curatively Resected Gastric Cancer
Date of disclosure of the study information 2013/08/12
Last modified on 2016/11/15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Exploratory Research on Prognosis Factors and Risk-factors of Adverse Drug Reactions in the Adjuvant Chemotherapy with S-1 for Patients with Curatively Resected Gastric Cancer
Acronym JACCRO GC-07 AR
Scientific Title Exploratory Research on Prognosis Factors and Risk-factors of Adverse Drug Reactions in the Adjuvant Chemotherapy with S-1 for Patients with Curatively Resected Gastric Cancer
Scientific Title:Acronym JACCRO GC-07 AR
Region
Japan

Condition
Condition Gastric Cancer
Classification by specialty
Gastroenterology Hematology and clinical oncology Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To assess the following items using the background factors such as clinical examination before start of administration and dosage form in the patients registered on JACCRO GC-07 study. 1. Predicting prognosis factors in the adjuvant therapies containing S-1 2. Risk-factors of adverse drug reactions in the adjuvant therapies containing S-1 3. Factors affecting the continuities of drug administration in the adjuvant therapies containing S-1
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes Correlations between the following items A and B
A:
1. 3-year and 5-year relapse-free survival
2. 3-year and 5-year overall survival
3. time to treatment failure
4. side-effects
5. continuity of S-1 administration
B:
1. 1) clinical examination: WBC, ANC, Lymphocite, PLF, Hb, bilirubin, AST, ALT, ALP, albumin, CRP, eGFR, creatinine, CCR, 2) Age,3) Sex, 4) Height, 5) Weight, 6) Surgical method, type of surgery, type of re-constraction, 7) number of resected lymphnodes, number of metastatic lymphnodes,8) Stage, 9) Histological classification, 10) lymphatic invasion, vein invasion, 11) tumor markers, 12) PS, 13) medication status and dosage of S-1, 14) medication status of docetaxel.
2. Prognostic nutritional index
3. Glasgow prognostic score
4. Neutrophili/lymphocite ratio
5. body weight loss
6. body mass index
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria Among the patients who were registered in JACCRO GC-07 (UMIN000010337), those who meet the following criteria.
1. following items within 14 days before surgery were obtained
1) WBC, ANC, Lymphocyte, ALP, Albumin, CRP
2) Weight
2. CEA and CA19-9 within 28 days before surgery were obtained
3. Written informed Consent
Key exclusion criteria 1. Patients who are judged as inadequate for study enrollment by investigators
Target sample size 880

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takeshi Sano
Organization Cancer Institute Hospital
Division name Department of Digestive Surgery
Zip code
Address 3-8-31 Ariake, Koto-ku, Tokyo, Japan
TEL 03-3520-0111
Email takeshi.sano@jfcr.or.jp

Public contact
Name of contact person
1st name
Middle name
Last name Masashi Fujii
Organization Nonprofit Organization Japan Clinical Cancer Research Organization
Division name Office
Zip code
Address 1-14-5 Ginza, Chuo-ku, Tokyo 104-0061, Japan
TEL 03-5579-9882
Homepage URL
Email gc07.dc@jaccro.or.jp

Sponsor
Institute Nonprofit Organization Japan Clinical Cancer Research Organization
Institute
Department

Funding Source
Organization TAIHO PHARMACEUTICAL CO., LTD.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions がん研有明病院(東京都)ほか、JACCRO参加施設

Other administrative information
Date of disclosure of the study information
2013 Year 08 Month 12 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2013 Year 06 Month 11 Day
Date of IRB
Anticipated trial start date
2013 Year 07 Month 17 Day
Last follow-up date
2022 Year 12 Month 31 Day
Date of closure to data entry
2023 Year 02 Month 28 Day
Date trial data considered complete
2023 Year 03 Month 31 Day
Date analysis concluded
2023 Year 06 Month 30 Day

Other
Other related information Exploratory Research on Prognosis Factors and Risk-factors of Adverse Drug Reactions in the Adjuvant Chemotherapy with S-1 for Patients with Curatively Resected Gastric Cancer
Prospective Study

Management information
Registered date
2013 Year 08 Month 10 Day
Last modified on
2016 Year 11 Month 15 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013104

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.